Our ambition and strategic priorities

Vicore is unlocking the potential of a new class of drugs – Angiotensin II Type 2 Receptor Agonists (ATRAGs) by pioneering the AT2 receptor – a target for resolution and repair. Patients motivate us to explore this protective resolution and repair system to address unmet medical needs and create value across multiple disease areas.

In IPF – our lead indication – we aim to be the preferred partner through a collaborative holistic patient centric approach throughout clinical trials and commercialization of:

  • Almee™ – addressing anxiety associated with pulmonary fibrosis
  • C21 – stabilizing disease and increasing lung capacity by promoting alveolar repair
  • Inhaled thalidomide – targeted approach addressing IPF cough

With our unique expertise in the ATRAG biology we fuel our pipeline with several new assets with long patent life for a variety of diseases. We partner with the scientific community and other companies to explore new indications and co-create patient value.